• Sosei Group Corp., of Tokyo, and Novartis AG, of Basel, Switzerland, said an application has been submitted for the registration of QVA149, an investigational fixed-dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide), as a once-daily treatment for chronic obstructive pulmonary disease in Japan.